François Mereau, is an investor in life science companies both at early stages and after their listing, with a focus on France and Western Europe. He is a member of the French business angels network Angels Santé where he has an active role in selecting the dealflow and completing the due diligence of candidate startups, the major therapeutics areas of biotech, as well as medtech and e-Health sectors. François has a previous background of 20 years in institutional investment on international markets in European banks (Fortis, Compagnie Financière Edmond de Rothschild), fund management companies (FP Consult, Threadneedle Asset Management London) and hedge funds (Adelante Asset Management London). In these positions, he had the responsibility of leading investment teams , achieving absolute returns objectives and monitoring risk for emerging markets hedge funds.
Joël Besse, has been an investor in, and an advisor of life sciences, emerging companies, for the past 27 years. He was the Managing Director of SED Ventures (since acquired by Paul Capital), a company investing internationally in biotech and medtech startups, and a Managing Partner of Atlas Venture, heading the European Life Sciences group. As such he led early-stage financings in multiple young companies, including listed and acquired companies Actelion Ltd. (SIX: ATLN), Newron Pharmaceuticals S.p.A. (SIX: NWRN), Nitec Pharma A.G. (NASDAQ: HZNP), Novamed Pharmaceuticals Inc. (NASDAQ:SCLN), Axovan A.G., U3 Pharma GmbH, Prestwick Pharma Inc., Novexel S.A., Novuspharma S.p.A., IDM Pharma Inc. and Arrow Therapeutics Ltd. Joël is a shareholder and/or advisor of multiple life sciences startup companies.